Delcath Systems, Inc., an interventional oncology company, has announced the approval of equity awards for eleven new employees who began their roles in March and April 2025. As part of the company's 2023 Inducement Plan, these grants allow the purchase of 111,000 shares of Delcath's common stock. Approved by the Compensation Committee, the stock options carry an exercise price of $12.04, reflecting the closing price on April 30, 2025. The vesting schedule stipulates that one-third of the options will vest after one year, with the remaining options vesting in equal monthly installments over the subsequent two years, contingent on continued employment. The options have a ten-year term. These moves align with Nasdaq Listing Rule 5635(c)(4).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.